Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Eden Biodesign and the University of Manchester Intellectual Property Limited Develop Innovative Treatment for Cancer

Published: Wednesday, August 08, 2007
Last Updated: Friday, August 10, 2007
Bookmark and Share
UMIP selects Eden Biodesign to provide a range of services for the development of therapeutic for treatment of macular degeneration and cancer.

Eden Biodesign Ltd has announced that it has been selected by UMIP to provide a range of services for the development of therapeutic for treatment of macular degeneration and cancer.

Professor Paul Bishop, School of Medicine, University of Manchester, who leads the team that discovered the new therapeutic, commented: “We are very pleased for this exiting programme to be further developed by Eden Biodesign. The experience of Eden Biodesign’s management team in the development of biologics ensures that our programme will be well positioned for an accelerated clinical development and will increase the value of our programme to industrial partners.”

“We look forward to helping UMIP and Professor Bishop to accelerate the transfer of this new therapy from research labs into clinical development”, said Dr Crawford Brown, CEO of Eden Biodesign. “Eden Biodesign has the expertise in product development and manufacturing that is critical to ensure clinical and commercial success of this product.”

Professor Paul Bishop has been awarded a grant from the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA) towards the cost of the project.

The project will be executed at the NBC, operated by Eden Biodesign and funded by NWDA, European Regional Development Fund (ERDF) and Department of Trade and Industry.

“We are pleased that the NBC is able to provide practical help to Professor Paul Bishop and UMIP Ltd for the commercialisation of their discoveries which have the potential to offer both patient benefit and consolidation of the UK’s lead in biopharmaceutical development in Europe” said Dr Linda Magee, NWDA Biotechnology Sector Director & Head of Bionow.

Dr Rich Ferrie, Head of BioMedica Operations at UMIP added, “This is the first of a number of our projects that should benefit from the excellent facilities at NBC and the product development expertise of Eden Biodesign. We believe that Opticin has tremendous therapeutic potential and the work package planned is an important next step in our strategy of partnering this programme.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Leukemia Gene Stops Blood Cells ‘Growing Up’
University of Manchester scientists have identified a gene – FOXC1 – that, if switched on, causes more aggressive cancer in a fifth of acute myeloid leukaemia (AML) patients, according to a Cancer Research UK study.
Wednesday, September 16, 2015
Molecular Clues to Serious Illnesses to be Explored
The University of Manchester is to lead a new £2.9 million molecular pathology research project to improve diagnosis and treatment of non-cancerous diseases within the NHS.
Friday, July 31, 2015
Gene Variants Show Potential In Predicting Rheumatoid Arthritis Disease Outcomes
Arthritis Research UK-funded scientists at The University of Manchester have identified a new way in which genotyping can be used to predict disease outcomes among sufferers of rheumatoid arthritis.
Thursday, April 30, 2015
Current Detection of Gene Mutations Misses People At High Risk Of Cancer
Research on the BRCA gene mutation in the Jewish population shows that the current process of identifying people misses half the people who have the mutation and are at risk of developing cancer.
Tuesday, December 02, 2014
Study Maps Human Metabolism in Health and Disease
Scientists have produced an instruction manual for the human genome that provides a framework to better understand the relationship between an individual’s genetic make-up and their lifestyle.
Monday, March 04, 2013
New Strategy in Fight against Cancer
Scientists have identified a new strategy in the fight against cancer, having found a mechanism for switching off a chemical signal that is intimately linked to progression of the disease.
Monday, September 22, 2008
Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos